

Cannabis for Medical Purposes

<https://policybase.cma.ca/en/permalink/policy10045>

Policy Type: Policy document
 Last Reviewed: 2019-03-03
 Date: 2010-12-04
 Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs

Documents



PD11-02.pdf

 Read PDF

 Download PDF



Chalk River National Research Universal reactor

<https://policybase.cma.ca/en/permalink/policy9919>

Policy Type: Policy resolution
 Last Reviewed: 2017-03-04
 Date: 2010-08-25
 Topics: Health systems, system funding and performance
 Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
 Resolution: GC10-102

The Canadian Medical Association urges the federal government to make a public commitment to keep the Chalk River National Research Universal reactor operational for as long as necessary beyond the announced date of 2016 and until secure alternative supplies of isotopes or alternative radiopharmaceuticals are proven and available.




Letter on cross-border pharmacy control


<https://policybase.cma.ca/en/permalink/policy1947>


Policy Type: Response to consultation
 Last Reviewed: 2013-03-02
 Date: 2005-11-08
 Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs

Documents



BR2006-03.pdf

 Read PDF

 Download PDF



Mental Health, Mental Illness & Addiction : CMA Submission to the Standing Committee on Social affairs, Science and Technology

<https://policybase.cma.ca/en/permalink/policy1950>

Policy Type: Parliamentary submission
Last Reviewed: 2012-03-03
Date: 2005-04-20
Topics: Population health/ health equity/ public health
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs

Documents

BR2005-05.pdf

Read PDF

Download PDF




Non-medicinal ingredients in drug products

<https://policybase.cma.ca/en/permalink/policy802>

Policy Type: Policy resolution
Last Reviewed: 2017-03-04
Date: 1985-08-25
Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution: GC85-28

The Canadian Medical Association calls on Health Canada to facilitate the dissemination of information to health professionals and consumers concerning the presence, in drug products, of non-medicinal ingredients that can cause adverse reactions.



A Prescription for Optimal Prescribing

<https://policybase.cma.ca/en/permalink/policy10016>


Policy Type: Policy document

Last Reviewed: 2016-05-20


Date: 2010-08-26


Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs

Documents



PD11-01.pdf

 Read PDF

 Download PDF




Study on Mental Health, Mental Illness and Addiction in Canada : Supplementary Submission to the Senate Standing Committee on Social Affairs, Science and Technology


<https://policybase.cma.ca/en/permalink/policy1945>

Policy Type: Parliamentary submission
Last Reviewed: 2013-03-02
Date: 2005-10-11
Topics: Population health/ health equity/ public health
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs

Documents

BR2006-01.pdf

 Read PDF

 Download PDF